3.2 Monitoring Visit Types: Site Selection, SIV, IMV, and Close-Out

The Mandate and Purpose of Clinical Monitoring (ICH E6(R3) Annex 1 section 3.11.4)

According to ICH E6(R3) Annex 1 section 3.11.4, the purpose of trial monitoring is to verify that:

1. The rights, safety, and well-being of human subjects are protected.
2. The reported trial data are accurate, complete, and verifiable from source documents.
3. The conduct of the trial is in compliance with the currently approved protocol/amendment(s), with Good Clinical Practice (GCP), and with applicable regulatory requirements.

To fulfill this mandate, Clinical Research Associates (CRAs / Monitors) conduct structured monitoring visits throughout the trial lifecycle. Each visit type serves a distinct purpose, requires specific entry prerequisites, and produces standardized documentation.

---

1. Pre-Study Visit (PSV) / Site Qualification Visit (SQV) / Site Selection Visit (SSV)

+-----------------------------------------------------------------------------+
|                   SITE QUALIFICATION VISIT (SQV / PSV)                      |
|  Goal: Determine if the site has the capability, facilities, staff, and    |
|  patient population to successfully conduct the specific clinical trial.    |
+-----------------------------------------------------------------------------+

Objectives

• Evaluate the qualifications, experience, and availability of the Principal Investigator (PI) and study personnel.
• Determine the adequacy of the site's patient pool and verify access to the target population.
• Assess physical facilities, equipment, diagnostic capabilities, and pharmacy storage.
• Identify competing clinical trials that might dilute recruitment.

Prerequisites

• Fully executed Confidential Disclosure Agreement (CDA / NDA) between the sponsor/CRO and the institution.
• Completed Site Feasibility Questionnaire.
• Protocol Synopsis or Draft Protocol provided to the PI for review.

Key Conduct Activities

1. Investigator Interview: Review the PI's Curriculum Vitae (CV), medical license, GCP training, past clinical trial experience, and personal time commitment to provide direct trial oversight.
2. Staff Assessment: Verify availability and qualifications of Sub-Investigators, Clinical Research Coordinators (CRCs), research nurses, and study pharmacists.
3. Patient Population Analysis: Review electronic medical record (EMR) search results, referral networks, historical enrollment in similar disease indications, and potential competing studies.
4. Facility & Equipment Inspection:
   • Investigational Pharmacy: Secure, temperature-controlled drug storage (ambient, 2–8°C, -20°C, -80°C), calibrated digital temperature monitoring devices with continuous 24/7 data logging, backup power generators, and controlled key/badge access.
   • Laboratory: Calibrated centrifuges (refrigerated vs. ambient), specimen processing areas, packaging/shipping facilities (IATA certified staff for dry ice / biohazard shipments).
   • Specialized Equipment: ECG machines, imaging facilities (MRI, CT, PET), infusion suites, emergency resuscitation equipment (crash carts with current expiration dates).
   • Monitoring Workspace: Dedicated space with high-speed internet, telephone access, and electronic health record (EHR) viewer access for CRAs.

Deliverables

• Site Qualification Report: CRA documents findings and provides a formal recommendation (Recommended, Conditionally Recommended with corrective steps, or Not Recommended).
• Confirmation of Selection / Non-Selection Letter sent to the PI.

---

2. Site Initiation Visit (SIV)

+-----------------------------------------------------------------------------+
|                        SITE INITIATION VISIT (SIV)                          |
|  Goal: Provide comprehensive training on the protocol, procedures, IP, and |
|  safety reporting to ensure site readiness BEFORE any subjects are screened.|
+-----------------------------------------------------------------------------+

Objectives

• Train the PI and all delegated site staff on the final approved protocol, study-specific procedures, laboratory manuals, and investigational product management.
• Confirm that all regulatory approvals and operational supplies are in place.
• Review investigator obligations, GCP standards, and electronic systems access.

Prerequisites: The "Greenlight" / Study Activation Package

An SIV can only occur (or enrollment authorization can only be granted) when the Regulatory Greenlight Package is complete:

• Institutional Review Board / Independent Ethics Committee (IRB/IEC) unconditional approval of the protocol, Investigator's Brochure, informed consent form (ICF), and recruitment materials.
• Competent Regulatory Authority clearance (e.g., FDA IND active status, EMA Clinical Trial Authorisation [CTA]).
• Fully executed Clinical Trial Agreement (CTA) and financial budget.
• Signed and dated Form FDA 1572 (for IND studies) or Investigator Agreement.
• Completed Financial Disclosure Forms (FDFs) for PI and all Sub-Investigators.
• Current CVs and medical/professional licenses for all investigators.
• IRB-approved Informed Consent Form (with correct version date and institutional watermarks).
• Investigational Product (IP) shipped to site or authorized for release.

Key Conduct Activities

1. Protocol Walkthrough: Detailed review of study objectives, inclusion/exclusion criteria, visit schedule, protocol-specified time windows, and endpoint assessments.
2. Delegation of Authority Log (DOAL): Verify that all staff performing protocol-specific tasks are listed, assigned appropriate roles matching their credentials, and that the PI has personally signed and dated the log.
3. Safety Reporting Workflows: Re-train staff on definitions of Adverse Events (AEs), Serious Adverse Events (SAEs), causality, expectedness, and the mandatory 24-hour reporting window for SAEs.
4. Investigational Product Management: Review receipt, storage conditions, temperature monitoring, reconstitution/preparation, dispensing, accountability logs, and unblinding procedures.
5. Electronic Systems Training: EDC system navigation, ePRO/eCOA devices, Interactive Response Technology (IRT/RTSM) for randomization and drug supply management.

Deliverables

• SIV Report and SIV Follow-Up Letter detailing any pending action items.
• Formal Site Activation / Greenlight Letter issued by the sponsor/CRO authorizing the site to begin screening and enrolling subjects.

---

3. Interim Monitoring Visit (IMV) / Routine Monitoring Visit (RMV)

+-----------------------------------------------------------------------------+
|                    INTERIM MONITORING VISIT (IMV / RMV)                     |
|  Goal: Ongoing oversight to ensure ongoing participant safety, protocol     |
|  compliance, source data verification/review, and trial integrity.          |
+-----------------------------------------------------------------------------+

Objectives

• Verify that informed consent was properly obtained and documented for every participant prior to performing any study-related procedure.
• Assess ongoing protocol compliance and identify deviations.
• Conduct Source Data Verification (SDV) and Source Data Review (SDR).
• Perform IP accountability and inspect storage conditions.
• Reconcile adverse events and confirm timely SAE reporting.
• Meet with the PI to review findings and establish corrective action plans.

Key Conduct Activities

Mandatory Log: Monitoring Visit Log

The CRA must sign the Site Monitoring Log on-site, recording the date of the visit, CRA name, organization, and visit purpose. This log remains in the Investigator Site File (ISF) and serves as official proof of oversight during regulatory inspections.

---

4. Close-Out Visit (COV)

+-----------------------------------------------------------------------------+
|                          CLOSE-OUT VISIT (COV)                              |
|  Goal: Formally reconcile all trial supplies, resolve all data queries,     |
|  and terminate trial operations at the site after study completion.         |
+-----------------------------------------------------------------------------+

Objectives

• Ensure all subjects have completed all scheduled visits or were appropriately withdrawn.
• Resolve 100% of outstanding data queries and freeze/lock the site database.
• Conduct final reconciliation and disposition of all investigational products and clinical trial materials.
• Ensure complete filing of essential documents and instruct the site on record retention requirements.

Key Conduct Activities

1. Final Subject Status Confirmation: Confirm final study disposition for all enrolled subjects (completed, withdrawn, lost to follow-up) and verify all end-of-study/safety follow-up visits occurred.
2. Query Resolution & Data Freeze: Confirm all EDC queries are resolved, all eCRFs are electronically signed by the PI, and local lab certification ranges are complete.
3. Final IP Reconciliation & Destruction: Perform 100% final count of all received, dispensed, lost, returned, and unused IP. Obtain sponsor written authorization for on-site destruction (with Certificate of Destruction) or arrange return shipment to the sponsor/depot.
4. Biological Sample Reconciliation: Verify that all pharmacokinetic (PK), pharmacodynamic (PD), or biomarker samples have been analyzed, shipped to central labs, or destroyed according to protocol.
5. Essential Documents & ISF Finalization: File final monitoring follow-up letters, final safety reports, and close-out documentation in the ISF.
6. Archiving & Retention Instructions: Provide written instructions regarding statutory record retention timelines (e.g., 2 years post-marketing approval under 21 CFR 312.62(c); minimum 25 years under EU CTR 536/2014; or per sponsor contract, whichever is longer). Remind PI to notify the sponsor in writing before destroying or moving records.
7. IRB Notification: Confirm the PI will submit the final study closure report to the IRB/IEC.

---

Summary Comparison of Monitoring Visit Types

---

CRA Communications and Action Item Management

1. Pre-Visit Confirmation Letter: Sent 2–4 weeks prior to the visit. Specifies visit dates, agenda, required site personnel availability (especially PI meeting time), list of subject charts to be pulled, and workspace needs.
2. Monitoring Report (Internal): Written by the CRA following sponsor SOPs, submitted within designated timelines (typically within 5–10 business days of visit completion) for manager review and Quality Assurance oversight.
3. Follow-Up Letter (to Site): Addressed to the PI within standard timelines (e.g., 10–15 business days post-visit). Summarizes visit activities, highlights significant findings/deviations, and details an Action Item Table specifying:
   • Description of the issue / deficiency.
   • Specific corrective action required.
   • Responsible person assigned (e.g., PI, CRC, Pharmacist).
   • Agreed-upon target completion date.
4. Action Item Tracking: The CRA tracks open action items from previous visits; persistent or unresolved non-compliance is escalated per the sponsor's clinical escalation SOP.